Regentis Biomaterials Ltd. (NYSEAM: RGNT)
Health Care · Biotechnology · IL
$1.49
-6.88% today · -86.5% 1Y
Regentis Biomaterials Ltd. (NYSEAM: RGNT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $10.47M and employs 10 people.
Over the last twelve months the share price has lost 86.5%, trading between 1.23 and 15.50.
Tweenvest scores Regentis Biomaterials Ltd. across four factors: quality 52/100, value 59/100. Its strongest factor is value.
RGNT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.47M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.66
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $15.50
- 52-week low
- $1.23
- Avg volume (3M)
- —
- Shares outstanding
- 7.02M
- Employees
- 10
- Next earnings
- —
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
- ISIN
- IL0012190968
- Founded
- 2004
- Listed since
- Dec 4, 2025
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Cellectar Biosciences, Inc.NasdaqCM: CLRB | $10.78M | $1.14 | -21.38% |
| Noxopharm LimitedASX: NOX | $10.69M | AU$0.05 | -18.03% |
| CytoMed Therapeutics LimitedNasdaqCM: GDTC | $10.50M | $0.88 | -1.13% |
| Ceryvyn Therapeutics LimitedASX: CYV | $10.47M | AU$0.01 | -15.38% |
| Palatin Technologies, Inc.LSE: 0KF3 | $10.33M | $5.80 | -3.33% |
| Tempest Therapeutics, Inc.NasdaqCM: TPST | $10.32M | $0.62 | -17.88% |
| Phio Pharmaceuticals Corp.NasdaqCM: PHIO | $10.12M | $0.87 | -11.00% |
| Ensysce Biosciences, Inc.NasdaqCM: ENSC | $10.08M | $0.52 | -1.65% |
Figures last refreshed Oct 18, 2026.